Genetic, molecular anomalies determine RCC therapy

Management of kidney cancer is advancing on several fronts, and this theme of continued progress is well illustrated by research being presented at the AUA annual meeting, said Robert C. Flanigan, MD.

Related Videos

Related Content

Advertisement

July 9th 2025

Optimizing SNM: PEER trials investigate potential of SNM lead sensing

Colin Goudelocke, MD Hannah Clarke

Colin M. Goudelocke, MD, discusses the PEER trials, which are assessing the safety and efficacy of SNM lead sensing for optimizing SNM programming.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 8th 2025

Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC

Benjamin P. Saylor Hannah Clarke

Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.

June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD

The conversation covers practical, case-based strategies for counseling MSM patients.

July 7th 2025

FDA and EMA authorize phase 3 trial of masitinib for mCRPC

Benjamin P. Saylor

For the trial, a biomarker will be utilized to aid in patient selection for the treatment.

July 7th 2025

Expanded indication sought for niraparib plus AAP in Europe

Hannah Clarke

The application is supported by data from the phase 3 AMPLITUDE trial.

Related Content

Advertisement

July 9th 2025

Optimizing SNM: PEER trials investigate potential of SNM lead sensing

Colin Goudelocke, MD Hannah Clarke

Colin M. Goudelocke, MD, discusses the PEER trials, which are assessing the safety and efficacy of SNM lead sensing for optimizing SNM programming.

June 30th 2025

Pearls & Perspectives: Disruptive Innovation in Urology, with Sijo J. Parekattil, MD

Amy M. Pearlman, MD

Pearlman and Parekattil dig deep into novel surgical and non-surgical approaches to chronic orchialgia and pelvic pain.

July 8th 2025

Enrollment complete for phase 3 UTOPIA trial in LG-IR-NMIBC

Benjamin P. Saylor Hannah Clarke

Eligible patients will receive UGN-103 75 mg intravesically once per week for 6 weeks.

June 19th 2025

Pearls & Perspectives: Sexual Health in MSM, with Joshua R. Gonzalez, MD

Amy M. Pearlman, MD

The conversation covers practical, case-based strategies for counseling MSM patients.

July 7th 2025

FDA and EMA authorize phase 3 trial of masitinib for mCRPC

Benjamin P. Saylor

For the trial, a biomarker will be utilized to aid in patient selection for the treatment.

July 7th 2025

Expanded indication sought for niraparib plus AAP in Europe

Hannah Clarke

The application is supported by data from the phase 3 AMPLITUDE trial.